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Abstract If (or Ih), encoded by the hyperpolarization-
activated, cyclic nucleotide-gated (HCN1–4) channel gene
family, contributes significantly to cardiac pacing. Brady-
cardic agents such as ZD7288 that target HCN channels
have been developed, but the molecular configuration of
their receptor is poorly defined. Here, we probed the drug
receptor by systematically introducing alanine scanning
substitutions into the selectivity filter (C347A, I348A,
G349A, Y350A, G351A in the P-loop), outer (P355A,
V356A, S357A, M358A in the P-S6 linker), and inner
(M377A, F378A, V379A in S6) pore vestibules of HCN1
channels. When heterologously expressed in human em-
bryonic kidney 293 cells for patch-clamp recordings,
I348A, G349A, Y350A, G351A, P355A, and V356A did
not produce measurable currents. The half-blocking con-
centration (IC50) of wild type (WT) for ZD7288 was 25.8±
9.7 μM. While the IC50 of M358A was identical to WT,
those of C347A, S357A, F378A, and V379A markedly
increased to 137.6±56.4, 113.3±34.1, 587.1±167.5, and
1726.3±673.4 μM, respectively (p<0.05). Despite the
proximity of the S6 residues studied, M377A was hyper-
sensitive (IC50=5.1±0.7 μM; p<0.05) implicating site
specificity. To explore the energetic interactions among
the S6 residues, double and triple substitutions (M377A/
F378A, M377A/V379A, F378A/V379A, and M377A/
F378A/V379A) were generated for thermodynamic cycle
analysis. Specific interactions with coupling energies
(ΔΔG) >1 kT for M377–F378 and F378–V379 but not
M377–V379 were identified. Based on these new data and
others, we proposed a refined drug-blocking model that
may lead to improved antiarrhythmics and bioartificial
pacemaker designs.
Keywords Drug . Inner pore . ZD7288 .
Pacemaker channels . HCN
Introduction
Pacemaker activity, the generation of spontaneous cellular
electrical rhythms, governs numerous biological processes
from the autonomous beating of the heart to respiratory
rhythms and sleep cycles [31]. In the heart, abnormal
pacing leads to various forms of arrhythmias (e.g., sick
sinus syndrome). If (or Ih in noncardiac tissues), encoded by
the hyperpolarization-activated, cyclic nucleotide-gated
(HCN1–4) channel gene family, is a key depolarizing
current in cardiac pacing that is activated by hyperpolar-
ization (rather than depolarization of classical voltage-gated
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ion channels) [15, 23, 27]. Familial mutations of the human
HCN genes have been described [24].
Structurally, each HCN channel consists of four homol-
ogous monomers pseudosymmetrically arranged around a
central pore, resembling voltage-gated K+ (Kv) channels;
each of the four internal repeats is made up of six
transmembrane segments (S1–S6; Fig. 1). The region
between S5 and S6, or the so-called P-loop, inserts back
into the membrane to form part of the pore. Indeed, the pore
is analogous to the active site of an enzyme where major
functional (e.g., ionic selectivity, conductance and gating)
and pharmacological determinants are located [31].
Given the physiological importance of If, bradycardic
drugs such as ZD7288 and ivabradine that target HCN
channels have been developed. However, the molecular
constituents of the HCN channel drug binding receptor
have not been fully elucidated. A better understanding is
crucial for designing more effective, HCN-specific drugs.
For voltage-gated K+ and Na+ channels, their drug binding
sites have been identified to reside in the pore regions [18].
Given the structural similarities between HCN and Kv
channels, it has been hypothesized that the drug receptor of
HCN channels is similarly located in the pore [5, 6, 12].
Shin and colleagues demonstrate that ZD7288 applied from
the cytoplasmic side can enter and leave the inner pore of
HCN1 channels only at voltages where the activation gate
is opened [30]. Using site-directed mutagenesis, Sanguinetti
and colleagues report that the S6 residues A425 and I432 of
HCN2 channels (the analogous residues are A372 and
V379 in HCN1) are primary determinants for ZD7288
block of wild-type (WT) HCN2 channels [12]. In the
present study, we first identified additional novel HCN pore
residues (C347, S357, M377, and F378 of HCN1) that are
crucial for bradycardic drug binding then further explored
their energetic interactions. Specific interactions with
coupling energies (ΔΔG) >1 kT for M377–F378 and
F378–V379 but not M377–V379 were identified. These
novel results are discussed in relation to the molecular
composition of the HCN drug receptor and the mechanism
of ZD7288 block as well as their implications in bradycar-
dic drug and bioartificial pacemaker designs.
Materials and methods
Molecular biology and heterologous expression Murine
HCN1 cDNA was cloned from mouse brain RNA [27]
and subcloned into the mammalian expression vector pCI
(Promega, Madison, WI, USA). Desired substitutions were
constructed as previously described [38]. HCN1 channels
were transiently expressed in human embryonic kidney 293
cells (HEK293) using Lipofectamine Plus 2000 (Invitrogen,
Carlsbad, CA, USA). For identifying HCN1-expressing
cells, the channel plasmid was cotransfected with pCI-green
fluorescent protein (GFP) with a ratio of 10:1. Twenty-four
hours to 48 h after transfection, cells were trypsinized and
plated on glass-bottomed culture dishes 2 h prior to patch-
clamp or immunohistochemical experiments.
Electrophysiology Whole-cell patch-clamp recordings were
performed using an EPC-10 patch-clamp amplifier (HEKA
electronic, Heidelberg, Germany). Only GFP-expressing
HEK293 cells as identified by their epifluorescence with an
excitation wavelength of 488 nm were selected for experi-
ments. All recordings were performed at room temperature
in a bath solution containing (in mM): 110 NaCl, 30 KCl,
1.8 CaCl2, 0.5 MgCl2, 5 HEPES, and 10 glucose, pH
adjusted to 7.4 with NaOH. The internal solution contained
(in mM): 10 NaCl, 130 KCl, 0.5 MgCl2, 5 HEPES, 1
Fig. 1 Schematic diagram and sequence alignment of the HCN1 and
KV channels. Upper panel: the six putative transmembrane segments
(S1–S6) of a monomeric HCN1 subunit. Ala scanning substitutions
were introduced into three different regions: selectivity filter (SF;
C347A, I348A, G349A, Y350A, G351A), outer (P355, V356, S357,
M358), and inner (M377A, F378A, V379A) pore vestibule. Lower
panel: the aligned amino acid sequences of HCN1-4 and Kv channels
from the P-loop to S6. Substituted residues are highlighted in bold
Fig. 2 Effects of the Ala and Ile substitutions in the pore region on
HCN1 currents. a Upper panel: representative recordings of WT
HCN1 using the voltage protocol provided in the inset. Trace a
−140 mV; trace b −100 mV; trace c −70 mV. Activation tail currents
are enclosed in dashed boxes and magnified to the right. Steady-state
activation relationship based on the tail current is also shown. Lower
panel: representative traces of whole-cell currents recorded from cells
expressing WT and different Ala-substituted constructs as indicated. b
Immunostaining showed that the six dysfunctional constructs (I348A,
G349A, Y350A, G351A, P355A, and V356A) were localized to the
membrane surface, in a manner similar to that of WT
b
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EGTA, and 5 MgATP, pH adjusted to 7.3 with KOH. The
electrode tip and series resistances were, respectively, ~3–4
and <10 MΩ. The sampling frequency was 1.25 kHz. Cell
capacitance and series resistance compensation were not
used. The cycle length of the protocols was 4.6 s. The
potentials were not corrected for the liquid junction
potentials of +20.3 mV.
Experimental protocols and data analysis The steady-state
current–voltage (I–V) relationship was determined by
plotting currents measured at the end of a 3-s pulse ranging
from −140 to −30 mV from a holding potential of −30 mV
against the test potentials. The voltage dependence of HCN
channel activation was assessed by plotting tail currents
measured immediately after pulsing to −140 mV as a
function of the preceding 3-s test pulse normalized to the
maximum tail current recorded. The data were fitted to the
Boltzmann functions using the Marquardt–Levenberg algo-
rithm in a nonlinear least squares procedure:
m ¼ 1= 1þ exp Vt  V1
2
 
=k
  
where Vt is the test potential; V1/2 is the half-point of the
relationship; k=RT/zF is the slope factor, and R, T, z, and F
have their usual meanings.
For half-blocking concentrations (IC50), the following
binding isotherm was used:
I=IO ¼ 1= 1þ blocker½ =IC50ð Þnð Þ
G349A
WT NC
G351A V356A
P-loop P-S6
b
P355AI348A Y350A
Fig. 2 (continued)
Fig. 3 Steady-state current voltage and activation curves. a Effects of
Ala and Ile substitutions on HCN1 steady-state current–voltage
relationships. b Representative tracings and steady-state activation
relationships
b
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where n is the Hill coefficient; IO and I are the peak
currents measured at the voltage indicated before and after
blocker application, respectively. All IC50 values reported
were calculated from individual determinations.
For thermodynamic cycle analysis [17], coupling coef-
ficients (Ω) and interaction energies (∆∆G) for various
mutant channel pairs were calculated from the corresponding
IC50 values with the equations below:
Ω ¼ ICConstructA50 =ICConstructAB50
 
= ICWT50 =IC
ConstructB
50
 
ΔΔG ¼ RT 1n Ω
where R is the gas constant (k × NA), and T is the absolute
temperature. The standard errors for ∆∆G were estimated
by dividing the square root of the sum of the variances of
the RT ln IC50 means by the square root of the degree of
freedom. Significant interactions were defined as ∆∆G>
1 kcal/mol as we and others previously reported [20]. All
data presented were the means±SEM. Statistical signifi-
cance (p<0.05) was determined using an unpaired Stu-
dent’s t test.
Immunostaining HEK293 cells were fixed in 4% parafor-
maldehyde for 15 min at 21°C, washed with phosphate-
buffered saline (PBS), and permeabilized with 0.1%
Trition-X-100/PBS. The cells were then blocked with
10% bovine serum albumin with 4% goat serum in PBS
for 2 h at 21°C. Fixed cells were incubated with the HCN1
rabbit polyclonal antibodies (Alomone Labs, Jerusalem,
Israel) at a dilution of 1:200 overnight at 4°C, followed by
incubation with fluorescent-labeled secondary antibodies
for 50 min at 21°C and visualization by fluorescent
microscopy.
Results
Effects of alanine (Ala) substitutions on HCN1 As a first
step, we generated a total of 12 singly Ala-substituted
HCN1 pore constructs that correspond to these regions:
C347A, I348A, G349A, Y350A, and G351A in the
ascending limb of the P-loop, P355A, V356A, S357A,
and M358A in the P-S6 linker that forms part of the
extrapore and M377A, F378A, and V379A in the S6
segment that constitutes part of the cytoplasmic pore mouth
(Fig. 2a). Of note, I432 of HCN2, the analogous residue to
V379 of HCN1, has been previously reported to involve in
ZD7288 interaction [12]. Taken together with the notion
that aromatic residues in S6 of K and Na channels
participate in drug binding, we therefore hypothesized that
the MFV377–379 triplet also contributes to ZD7288 binding.
As anticipated from our previous results [38], substituting
residues 349–351 of the GYG motif (i.e., G349A, Y350A,
G351A) that is crucial for permeation did not produce
measurable currents. I348A, P355A, and V356A channels
were also not functional. Immunostaining indicated that all
nonfunctional constructs were membrane-localized similar
to WT (Fig. 2b), suggesting that the loss of function did not
result from defects in protein synthesis or trafficking. In
stark contrast, all of C347A, S357A, M358A, M377A,
F378A, and V379A channels expressed robust time-
dependent hyperpolarization-activated currents (Fig. 2a).
The corresponding steady-state current–voltage (I–V) rela-
tionships are shown in Fig. 3a. The different activation
thresholds hint that the gating properties of some of these
Ala-substituted pore constructs have been altered. To test
this notion, we next examined their steady-state activation
properties (Fig. 3b). Indeed, all of C347A (P-loop), S357A,
and M358A (P-S6), M377A, and V379A (S6) similarly and
significantly hyperpolarized the steady-state activation
midpoint (V1/2, Con) of WT from −62.6±1.4 mV (n=6) to
−82.1±4.7 (n=3), −76.1±0.3 (n=3), −70.8±1.6 (n=5),
−77.4±1.6 (n=4) and −97.8±2.6 (n=8) mV, respectively
(p<0.05). By contrast, F378A (of S6) caused a noticeable
opposite depolarizing shift (V1/2, Con=−56.2±3.7 mV, n=3)
although the difference did not reach statistical significance
(p=0.09). Of note, C347A, F378A, and V379A increased
the slope factor (k) by ~2-fold, twofold, and fivefold,
respectively (p<0.05).
Effects of Ala substitutions on current blockade by
ZD7288 To investigate the effect of our pore substitutions
on drug block, we started by characterizing the response of
WT HCN1 to ZD7288. Figure 4a shows that ZD7288 dose-
dependently reduced the maximum steady-state current of
WT at −140 mV. The half-blocking concentration or IC50
estimated from the binding curve was 25.8±9.7 μM (n=5).
The steady-state I–V and activation curves recorded in the
absence and presence of ZD7288 are given in Fig. 4b, c,
respectively. Figure 5 summarizes the effect of Ala
substitutions on ZD7288 blockade. C347A, S357A, F378A,
and V379A significantly shifted the binding curve in the
rightward direction. Their IC50s were 137.6±56.4 (n=4),
113.3±34.1 (n=5), 587.1±167.5 (n=3), and 1,726.3±
673.4 μM (n=3), respectively. Despite the proximity of
M377 to F378 and V379 in the primary sequence of S6, its
Ala substitution exerted an opposite effect on ZD7288 block
Fig. 4 ZD7288 block of mHCN1 channels. a Representative current
tracings and dose–response relationship for ZD7288 block of WT
HCN1 channel. Normalized steady-state currents at −140 mV were
plotted as a function of extracellular ZD7288 concentrations. Data
points were fitted with a binding isotherm to estimate the IC50 for
ZD7288 of the channel. b The steady-state current–voltage relation-
ships of WT HCN1 channel in the absence and presence of ZD7288. c
The corresponding steady-state activation curves for WT HCN1
channel. d The steady-state activation curves for the mutant HCN1
channels
b
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Fig. 5 Effects of Ala substitutions on ZD7288 block. a Upper panel: current tracings recorded at −140 mV in the presence of ZD7288 at different
concentrations. Lower panel: the dose–response curves. b Summary of IC50. Dashed line indicates the level of WT sensitivity (*, p<0.05)
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(IC50=5.1±0.7 μM, n=3; p<0.05). The Met-to-Ala at
residue 358 (i.e., M358A), however, was not different from
WT (p>0.05). Collectively, these observations suggest that
the effects of our Ala pore substitutions on ZD7288 block
were site specific. Similar to the hyperpolarizing shifts
observed for WT HCN1 channels, ZD7288 likewise caused
leftward activation shifts curves of Ala-substituted HCN
channels at concentrations comparable to the corresponding
IC50s. Interestingly, 1 mM ZD7288 nearly restored the WT
slope factor of V379A. These results hint at a gating effect of
ZD7288 on HCN channels as do local anesthetics on K+ and
Na+ channel gating.
Energetic interactions among the MFV377–379 triplet in
S6 Among all the pore sites investigated, the S6 residues of
the MFV377–379 triplet, which are in close proximity to each
other, when Ala-substituted produced the most significant
changes in their responses to ZD7288 and gating properties,
consistent with the role of S6 residues in drug binding. To
explore their energetic interactions, three double (M377A/
F378A, M377A/V379A, and F378A/V379A) and triple
substitutions (M377A/F378A/V379A) were generated for
thermodynamic cycle analysis. All constructs led to robust
current expression. As for ZD7288 blockade assessed at
−140 mV, the IC50 values as estimated from the dose–
response curves of M377A/F378A, M377A/V379A,
F378A/V379A, and M377A/F378A/V379A channels were
2,253.8±378.6 (n=6), 313.5±79.4 (n=4), 1,267.0±484.1
(n=6), and 2,027.4±1,100.9 μM (n=4), respectively
(Fig. 6; p<0.05). To calculate their interaction energies
with each other, a representative cycle analysis was given in
Fig. 7a as illustration. The coupling coefficient (Ω) for the
interaction pair M377–F378 calculated from WT, M377A,
F378A, and M377A/F378A was 0.05±0.01. Using the
corresponding single and double substitutions, the M377–
V379 and F378–V379 pairs were calculated to have Ωs of
1.09±0.21 and 31.0±9.09, respectively. Their absolute
interacting energies were −1.77±0.09, 0.05±0.13, and
2.03±0.18 kcal/mol, respectively (Fig. 7b). These results
indicate that significant interactions exist for the pairs
M377–F378 and F378–V379 but not M377–V379.
As a means to verify the specificity of our results
presented above, we constructed the triple construct
M377A/F378A/V379A for further cycle analyses. To
calculate the interaction of the pair M377–F378 in the
background of V379A, the combination of V379A,
M377A/V379A, F378A/V379A, and M377A/F378A/
V379A was employed. The Ω and ΔΔG calculated for
the pair were 0.11±0.01 and −1.31±0.10 kcal/mol (or
−2.21±0.15 kcal/mol), respectively. Using the same ap-
proach, the Ω and ΔΔG for the pairs of F378–V379 in the
M377A background and M377–V379 in the F378A
background were 68.17±9.09 and 4.22±0.54 and 2.40±
0.21 and 0.88±0.24 kcal/mol, respectively. In other words,
the same rank order for interactions as those calculated
from WT and single and double substitutions was
observed.
V379I displayed WT gating and ZD7288 phenotypes
Isoform-specific differences in bradycardic drug block of
HCN1 and HCN4 by the ivabradine have been reported [7].
Of note, the analogous residues of V379 of HCN1 are
isoleucines in HCN2, HCN3, and HCN4 (Fig. 1). However,
V379I displayed gating and ZD7288 sensitivity not
different from WT (Figs. 2, 3, and 5).
Discussion
In the present study, we probed the molecular constituents of
the drug binding receptor in HCN channels by Ala scanning
mutagenesis of three distinct pore regions: the selectivity
filter and the outer and the inner pore vestibules. Among the
pore residues examined, the S6 triplet MFV377–379 appears
to play the most significant role in determining the WT
drug-blocking phenotype. When Ala-substituted, residues
M377, F378, and V379 significantly affected the sensiti-
vity of HCN1 channels to the bradycardic drug ZD7288
by up to 67-fold (versus the ~3-fold differences of the P-
and P-S6 constructs). This finding is consistent with the
notion that the inner pore region is crucial for drug
binding as demonstrated by numerous previous Kv and
Nav channel studies [18]. Despite their proximity in the
primary sequence, M377A enhanced whereas F378A and
V379A reduced ZD7288 block. Furthermore, thermody-
namic cycle analysis revealed that the pairs M377–F378
and F378–V379, but not M377–V379, energetically
interact. Importantly, whereas M377 and F378 negatively
interact with other in drug binding, the interaction
between residues F378 and V379 is positive. The same
common pattern was observed when channel backgrounds
other than WT were employed for cycle analyses. These
differential effects strongly support that the observed
changes in ZD7288 block were highly site specific.
Sequence alignments and comparison with the known
crystal structures of Kv channels suggest that the side chain
of S6-V379 of HCN1 faces the aqueous phase of the
cytoplasmic pore. In Shaker K+ channels, the hydrophobic
binding pocket for quaternary ammonium compounds
consists of T469 in S6 [13]; the analogous residue of
Shaker’s T469 in HCN1 is C374. Our results indicate that
C347A display a fourfold reduction in ZD7288 sensitivity.
Taken together with the present findings that the S6
substitutions F378A and V379A (but not M377A) reduce
ZD7288 block, we propose that residues F378 and V379
are located on the same side of the S6-MFV377–379 helical
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turn that is exposed to the cytoplasmic pore. This spatial
arrangement is consistent with our thermodynamic cycle
analysis that energetic interactions exist only for the pairs
M377–F378 and F378–V379 but not M377–V379. Along
with the P-loop residue C374, the F378/V379 helical face
forms a receptor pocket to which ZD7288 binds. Although
the S6 residue M377 faces a different side of the S6-
MFV377–379 helix, it regulates the pathway by which the
drug molecule travels to its F378–V379 binding pocket:
when M377 is substituted by the smaller alanine, drug
access is improved, sterically and/or by relieving some
negative interactions, thereby facilitating ZD7288 block.
This proposed mechanism is also consistent with the
negative coupling identified for the M377–F378 pair. Our
model is schematically presented in Fig. 8.
Although chemical and structural differences exist for
ZD7288 and other HCN channel blockers (such as
ivabradine, cilobradine, and zatebradine), Ile432 of
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HCN2, a residue homologous to Val379 in the MFV377–379
triplet of HCN1, has also been shown to be involved in
cilobradine binding [12]. Further investigations will be
needed to test whether there is a single common receptor in
HCN channels for these drugs or there are multiple
overlapping and/or nonoverlapping drug binding sites.
The interacting MFV triplet that we have identified in the
present study appears to be a prime candidate for testing
these possibilities.
Though we have identified key residues that determine
ZD7288 block of HCN1 channels and energetically
quantified their interactions, the nature of their side chain
interactions with ZD7288 remains to be explored. The
spatial proximity of these key residues during the drug-
bound state, their accessibility, state dependent or not, from
the extracellular and cytoplasmic sides also require addi-
tional experiments (e.g., cysteine scanning mutagenesis).
For nonfunctional single Ala-substituted channels, the
generation of tandem constructs with one, two, or three
copies of a mutation introduced the pore may shed insights
into their roles in drug block.
To date, four isoforms, namely HCN1–4, have been
identified. These isoforms exhibit different patterns of gene
expression and tissue distribution [23, 25–28] and coas-
semble to form heteromeric complexes (except between
HCN2 and HCN3) that underlie the native If [11, 36, 38].
Although the primary sequences of the HCN1-4 pores are
highly conserved, three of the residues substituted in this
study, V356, S357, and V379, are isoform variants (Fig. 1).
While S357A only modestly contributes to ZD7288
binding and V356A abolishes channel function (which
prevents any direct conclusion about its pharmacological
role to be drawn), we have identified V379 as a deter-
minant of drug sensitivity and proposed that it con-
stitutes part of the drug receptor. The isoforms HCN1
and HCN2 are known to display different drug sensi-
tivities. Although residue 379 is an isoform variant,
V379I has gating properties and ZD7288 sensitivity not
different from WT murine HCN1. Thus, further experi-
ments will be needed to investigate the basis of
isoform-specific drug block. In stark contrast, the
homologous substitution V390I in human HCN1 mark-
edly increases the ZD7288 sensitivity rendering it
HCN2-like [12]. These results suggest that species- as
well as isoform-specific differences in drug block exist.
Further experiments will be needed to investigate the basis
of these differences. Given the fact that native If (or Ih)
currents from various tissues have diverse molecular
identities due to the different isoforms expressed and their
coassembly, a better understanding of drug block of
HCN1–4 channels is crucial for developing tissue-selective
If blockers.
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HCN-encoded If (or Ih) is one of the key players that
prominently modulate the rhythmic firing activity of
cardiac nodal pacemaker. For the heart, idiopathic and
familial sinus dysfunctions associated with human HCN
mutations have been reported [24, 29]. Although cardiac If
is most abundant in the sino-atrial node, it is also found at
various levels in the atrioventricular node, the Purkinje
fibers, the atria, and the ventricles [8, 9, 14]. Indeed,
upregulation of If has been suggested to contribute to atrial
ectopy and other arrhythmias associated with heart failure,
hypertrophy, and hypertension [8, 9, 14]. As a result,
drugs that target HCN channels such as ivabradine,
ZD7288, have been developed. Using an engineered
HCN1 channel with the S3–S4 linker residues 277–279
deleted [33, 34], we have successfully constructed an in
vivo bioartificial cardiac pacemaker that suffices to replace
or supplement conventional electronic devices in a large
animal sick sinus syndrome model [35, 39]. Thus, our
present results may be useful for designing future HCN
drugs and engineered HCN channels with a custom-
tailored modulatory drug receptor for gene- [35, 39] and
cell-based [21, 32] therapies. For instance, the substitution
M377A can be combined with others to generate a
bioartificial pacemaker that is ultrasensitive to bradycar-
diac drugs to confer drug specificity and to minimize
potential side effects (due to blockade of endogenous If or
Ih in other tissues).
Of note, the HCN1 isoform examined in the present study
is the least sensitive to cAMP among HCN1–4. HCN1 has
been chosen because we have previously extensively studied
its structure–function properties [1–4, 16, 19, 31, 33, 34, 37,
38]. Indeed, we have even successfully employed an
engineered HCN1 channel for constructing bioartificial
pacemakers both in vitro and in vivo [10, 22, 35, 39].
Although the least sensitive, HCN1 nonetheless responds to
adrenergic stimulations [35]. The present results will also be
particularly useful for improving antiarrhythmic designs and
selectivity. Nevertheless, further experiments at physiological
temperature, though more technically difficult to perform and
thus missed in the present study [40], will be useful to
examine the temperature-dependent effect as low temper-
atures was shown to possibly attenuate If inhibition [41].
In summary, we conclude that pore residues C347, F378,
and V379 of HCN1 channels are crucial for ZD7288 block.
Together, these amino acids may constitute part of the drug
binding receptor that is located relatively deep into the
pore. These P-loop and the S6 residues exert their effects by
modulating drug access to the receptor and by stabilizing
the drug-bound HCN channel complex. Therefore, we
proposed a refined drug-blocking model that may lead to
more improved antiarrhythmics and bioartificial pacemaker
designs, in particular, to provide better insights in improv-
ing drug selectivity.
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